Evidence map›Paper›PMID 42649193›Full record

ArticleNature communications2026

Heritable transgenic schistosomes as a living platform for SARS-CoV-2 neutralizing antibody secretion.

Wannaporn Ittiprasert, Michael J Smout, Victoria H Mann, Matthew Moyle, Sean M Kinahan, Daniel N Ackerman, Danielle N Rivera, Joshua L Santarpia, Eric C Carnes, Margaret M Mentink-Kane and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Wannaporn Ittiprasert1Department of Microbiology, Immunology & Tropical Medicine, School of Medicine & Health Sciences, George Washington University, Washington, D.C, USA.ORCID 0000-0001-9411-8883
Michael J SmoutAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.ORCID 0000-0001-6937-0112
Victoria H Mann1Department of Microbiology, Immunology & Tropical Medicine, School of Medicine & Health Sciences, George Washington University, Washington, D.C, USA.
Matthew MoyleAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.
Sean M KinahanDepartment of Pathology, Microbiology and Immunology, College of Medicine, and Global Center for Health Security University of Nebraska Medical Center, Omaha, NE, USA.
Daniel N AckermanDepartment of Pathology, Microbiology and Immunology, College of Medicine, and Global Center for Health Security University of Nebraska Medical Center, Omaha, NE, USA.
Danielle N RiveraDepartment of Pathology, Microbiology and Immunology, College of Medicine, and Global Center for Health Security University of Nebraska Medical Center, Omaha, NE, USA.
Joshua L SantarpiaDepartment of Pathology, Microbiology and Immunology, College of Medicine, and Global Center for Health Security University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0002-9837-2341
Eric C CarnesBiological Defense Directorate, National Strategic Research Institute, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0009-0007-3877-3008
Margaret M Mentink-KaneSchistosomiasis Resource Center, Biomedical Research Institute, Rockville, MD, USA.
Marina Reis Costa1Department of Microbiology, Immunology & Tropical Medicine, School of Medicine & Health Sciences, George Washington University, Washington, D.C, USA.
Cornelis H HokkeLeiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0003-3545-7804
Meta RoestenbergLeiden University Medical Centre, Leiden, The Netherlands.ORCID 0000-0002-5052-2830
Maria Elena BottazziNational School of Tropical Medicine, College of Medicine, Houston, TX, USA.ORCID 0000-0002-8429-0476
Bethany K BrackenCharles River Analytics, Cambridge, MA, UK.
Bruce A RosaDepartment of Medicine, Washington University of St. Louis School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-6820-446X
Sergej DjuranovicDepartment of Cell Biology and Physiology, Washington University of St. Louis School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-9417-0822
Darren A PickeringAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.ORCID 0000-0002-7517-8773
Paul R GiacominAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.ORCID 0000-0002-6326-6792
Daniel WattersonSchool of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD, Australia.ORCID 0000-0001-5957-2853
Naphak ModhiranSchool of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, QLD, Australia.ORCID 0000-0003-3205-4970
Max F MoescheidInstitute of Parasitology, Biomedical Research Center Seltersberg, Justus Liebig University, Giessen, Germany.ORCID 0000-0001-5007-3687
Christoph G GreveldingInstitute of Parasitology, Biomedical Research Center Seltersberg, Justus Liebig University, Giessen, Germany.ORCID 0000-0002-3144-2026
Makedonka MitrevaDepartment of Medicine, Washington University of St. Louis School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-9572-3436
Alex LoukasAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia. alex.loukas@jcu.edu.au.
Paul J Brindley1Department of Microbiology, Immunology & Tropical Medicine, School of Medicine & Health Sciences, George Washington University, Washington, D.C, USA. pbrindley@gwu.edu.ORCID 0000-0003-1765-0002

Funding

Targeting parasite-host communication to combat liver fluke-induced bile duct cancerR01CA164719 · NCI · GEORGE WASHINGTON UNIVERSITY · PI Paul J Brindley, THEWARACH LAHA · 2012 to 2026
$5.0M
MECHANISMS FOR MODULATION OF MIRNA-MEDIATED GENE SILENCINGR01GM112824 · NIGMS · WASHINGTON UNIVERSITY · PI DJURANOVIC, SERGEJ · 2015 to 2023
$3.1M
Dissecting mRNA-ribosome interaction in AU-rich transcriptome of Plasmodium falciparumR01GM136823 · NIGMS · WASHINGTON UNIVERSITY · PI DJURANOVIC, SERGEJ · 2021 to 2024
$1.4M
Mechanisms of translational controlR35GM161601 · NIGMS · BROWN UNIVERSITY · PI Sergej Djuranovic · 2026 to 2026
$584k
Deutsche Forschungsgemeinschaft (German Research Foundation) GR 1549/12-1NCI NIH HHS R01 CA164719NIAID NIH HHS HHSN272201000005CNIAID NIH HHS HHSN272201000005INIGMS NIH HHS R01 GM112824NIGMS NIH HHS R01 GM136823NIGMS NIH HHS R35 GM161601United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) N66001-21-C-4013U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) CA164719Wellcome TrustWellcome Trust (Wellcome) 107475/Z/15/Z
6 · The paper itself

Abstract

We report the generation and propagation of not only the first heritable transgenic schistosome line but also a line that secretes a functional therapeutic protein in vivo. Using multiplexed CRISPR/Cas-mediated homology-directed knock-in targeted to a predicted genomic safe-harbor, we inserted a VHH-IgG1 Fc (termed C5-Fc) transgene into Schistosoma mansoni eggs. Single-miracidium infections of Biomphalaria glabrata yielded parental P0 lines; serial passage through snail and mouse hosts produced an F2 cohort in which all parasites carried the C5-Fc transgene and secreted C5-Fc into the murine venous circulation. Molecular assays confirmed chromosomal insertion, germline transmission and systemic secretion. Sera from mice harboring C5-Fc transgenic worms neutralized SARS-CoV-2 in vitro with potent activity consistent with the expected ACE2-binding blockade by the C5 variable domain of heavy-chain-only antibody (VHH). These results demonstrate (i) stable, heritable transgenesis of a platyhelminth, (ii) delivery of a biologically active antibody fragment by a live helminth in a mammalian host, and (iii) feasibility of using transgenic schistosomes as sustained, single-dose protein delivery platforms. This technology and delivery system enable new experimental approaches for schistosome biology and motivate exploration of living-foundry therapeutics.

Indexed as

Animals, Genetically ModifiedAntibodies, NeutralizingAntibodies, ViralSARS-CoV-2Schistosoma mansoniAngiotensin-Converting Enzyme 2AnimalsBiomphalariaCOVID-19FemaleHumansImmunoglobulin Fc FragmentsImmunoglobulin GMiceAce2 protein, mouseAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralImmunoglobulin Fc FragmentsImmunoglobulin G

Identifiers

PMID42649193
PMCPMC13518888

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.